Immunic, Inc. Reports Q2 2026 Financial Results and Updates

Immunic, Inc., a biotech firm focusing on novel therapies for neurologic diseases, has released its second-quarter 2026 financial results. During the quarter, the company expanded its leadership with key appointments to support its clinical development efforts and commercial readiness.

The company is progressing with its pivotal Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis, with top-line data expected by the end of 2026. Preparations are also underway for a Phase 3 trial targeting progressive multiple sclerosis.

Financially, Immunic reported a net loss of $34.1 million for the quarter, compared to $26.8 million in the same period last year. R&D expenses rose to $25.9 million, driven by increased personnel costs and drug interaction studies. Cash reserves stood at $155.1 million, expected to fund operations into late 2027.